Product Information

ROFLUMILAST 250 MCG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $1.8047 per EA under NDC 67877073093. Its NADAC has been published 71 times since Jul 9, 2025.

FDA first approved this application on Apr 18, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ROFLUMILAST 250 MCG TABLET

Roflumilast
$1.8047per EA

Strength

250 ug/1

NDC

67877073093

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

ROFLUMILAST

Approval Type

Generic (ANDA)

FDA Application

ANDA212490

FDA Approved

4/18/2023

TE Code

AB

On Market Since

3/14/2025

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price Statistics

The NADAC for ROFLUMILAST 250 MCG TABLET has been published 71 times since Jul 9, 2025, and over the history we have for it it has declined 20.5%. The table below summarizes its recorded NADAC range and movement.

Current price$1.8047 per EA
All-time high$2.4855 (Sep 10, 2025)
All-time low$1.8047 (Oct 21, 2026)
52-week high$2.3109
52-week low$1.8047
Median price$2.1909
Average price$2.1479
Largest weekly change-8.9% (Oct 21, 2026)
Weeks tracked71
Tracking sinceJul 9, 2025

Price History

1W

0.0%

1M

-8.9%

3M

-7.9%

6M

-7.4%

1Y

-23.2%

3Y

N/A

5Y

N/A

All

-20.5%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ROFLUMILAST 250 MCG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Ascend Laboratories, LLC, is $1.8047 per EA (NDC 67877073093), effective Nov 11, 2026.

How has the price of ROFLUMILAST 250 MCG TABLET changed over time?

Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 20.5%. It has been tracked across 71 weekly CMS publications since Jul 9, 2025.

What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?

Since Jul 9, 2025, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.8047 (Oct 21, 2026) to a high of $2.4855 (Sep 10, 2025), with a median of $2.1909 per EA.

Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?

4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROFLUMILAST 250 MCG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures ROFLUMILAST 250 MCG TABLET?

ROFLUMILAST 250 MCG TABLET (NDC 67877073093) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.